Memo Therapeutics AG’s CHF20 Million Additional Series C Financing Round

Marco Zingaro
Tagged:

VISCHER advised Ysios Capital and Kurma Partners.Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised CHF20…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Marco Zingaro

…

This content is for Standard 1 Year members only.
Login Join Now